Association between the Fatty Liver Index, Metabolic Dysfunction-Associated Steatotic Liver Disease, and the Risk of Kidney Stones

被引:0
|
作者
Zhang, Fan [1 ,2 ,3 ]
Li, Wenjian [1 ,4 ]
机构
[1] Xuzhou Med Univ, Changzhou Clin Coll, Changzhou, Peoples R China
[2] Changzhou Third Peoples Hosp, Dept Endocrinol, Changzhou, Peoples R China
[3] Changzhou Third Peoples Hosp, Dept Clin Nutr, Changzhou, Peoples R China
[4] Changzhou Third Peoples Hosp, Dept Urol, Changzhou, Peoples R China
关键词
Fatty liver index; Metabolic dysfunction-associated steatotic liver disease; Kidney stones; Risk factors; NHANES; BODY-MASS INDEX; NEPHROLITHIASIS; PATHOGENESIS; NAFLD;
D O I
10.1159/000543404
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Introduction: This study aimed to investigate the potential association between the fatty liver index (FLI), metabolic dysfunction-associated steatotic liver disease (MASLD), and the risk of kidney stones using large-scale population-based data. Methods: This study employed a cross-sectional design, utilizing data from the 2007 to 2018 National Health and Nutrition Examination Survey (NHANES) database. A total of 24,342 participants were enrolled in the study, and fatty liver status was assessed by calculating the FLI. MASLD was diagnosed by FLI in conjunction with cardiometabolic criteria. Data on the history of kidney stones were obtained by self-report. We employed logistic regression models to analyze the association between FLI, MASLD, and kidney stone risk and constructed multivariable adjustment models to control for potential confounders. Furthermore, we used restricted cubic spline curve models to investigate the dose-response relationship between FLI and kidney stone risk and conducted subgroup and interaction analyses. Results: The study's results indicate a strong correlation between increasing FLI quartiles and a notable rise in the prevalence of kidney stones. Specifically, the risk of developing kidney stones was 1.68 times higher among participants in the highest FLI quartile compared to those in the lowest. Furthermore, patients with MASLD exhibited a 1.35-fold increased risk of developing kidney stones compared to those with non-MASLD. Subgroup analyses demonstrated that the correlation between MASLD and kidney stone risk was consistent across multiple subgroups. However, a significant interaction was observed in the subgroups of smoking status, physical activity level, and hypertension (interaction p < 0.05). The restricted cubic spline analysis did not yield a statistically significant nonlinear association between FLI and kidney stone risk. However, the study did identify inflection point values for FLI. Conclusion: This study demonstrated an association between FLI and MASLD and the risk of kidney stones. This suggests that these conditions may be pivotal risk factors for kidney stones. Further investigation is required to elucidate these associations' underlying mechanisms and develop efficacious interventions to reduce the risk of kidney stones. Also, formulating personalized prevention and treatment strategies for different population subgroups is paramount.
引用
收藏
页码:115 / 130
页数:16
相关论文
共 50 条
  • [31] Association between metabolic dysfunction-associated fatty liver disease and abdominal aortic aneurysm
    Jia, Yu
    Li, Yizhou
    Yu, Jing
    Jiang, Wenli
    Liu, Yi
    Zeng, Rui
    Wan, Zhi
    Liao, Xiaoyang
    Li, Dongze
    Zhao, Qian
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2024, 34 (04) : 953 - 962
  • [32] Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
    Bhopale, Kamlesh K.
    Srinivasan, Mukund P.
    LIVERS, 2023, 3 (04): : 597 - 617
  • [33] Correlation Between Metabolic Dysfunction-Associated Steatotic Liver Disease and the Risk of Urinary Incontinence in Adult Women
    Zhang, Fan
    Li, Wenjian
    INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2024, 16 : 1607 - 1624
  • [34] Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease
    Lim, Soo
    Kim, Jin-Wook
    Targher, Giovanni
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2021, 32 (07) : 500 - 514
  • [35] Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases
    Xiao, Yiyuan
    Xu, Sihua
    Hu, Wenyan
    Huang, Jiapeng
    Jiang, Deke
    Na, Rong
    Yin, Zhaoqing
    Zhang, Jingjing
    Chen, Haitao
    ANNALS OF HEPATOLOGY, 2025, 30 (01)
  • [36] Association between diet soft drink consumption and metabolic dysfunction-associated steatotic liver disease: findings from the NHANES
    Yanrui Wu
    Zongbiao Tan
    Junhai Zhen
    Chuan Liu
    Jixiang Zhang
    Fei Liao
    Weiguo Dong
    BMC Public Health, 23
  • [37] Cross talk between the liver microbiome and epigenome in patients with metabolic dysfunction-associated steatotic liver disease
    Pirola, Carlos Jose
    Salatino, Adrian
    Gianotti, Tomas Fernandez
    Castano, Gustavo Osvaldo
    Garaycoechea, Martin
    Sookoian, Silvia
    EBIOMEDICINE, 2024, 101
  • [38] Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions
    Beygi, Mohammad
    Ahi, Salma
    Zolghadri, Samaneh
    Stanek, Agata
    NUTRIENTS, 2024, 16 (14)
  • [39] Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease
    Long, Qichen
    Luo, Fengming
    Li, Binghui
    Li, Ziyang
    Guo, Zhe
    Chen, Zhiyang
    Wu, Weimin
    Hu, Min
    HEPATOLOGY COMMUNICATIONS, 2024, 8 (03)
  • [40] Association between life's essential 8 and metabolic dysfunction-associated steatotic liver disease among US adults
    Wang, Zheng
    Huang, Bohan
    Ding, Yixuan
    Cao, Feng
    Li, Fei
    Li, Prof Fei
    ARCHIVES OF PUBLIC HEALTH, 2024, 82 (01)